The Cooper Cos. (NYSE:COO) saw unusually-strong trading volume on Wednesday . Approximately 698,480 shares were traded during mid-day trading, an increase of 75% from the previous session’s volume of 400,114 shares.The stock last traded at $185.45 and had previously closed at $186.41.

A number of equities research analysts have recently issued reports on COO shares. Jefferies Group increased their price target on shares of The Cooper Cos. from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Wednesday, August 24th. Stifel Nicolaus lifted their price target on shares of The Cooper Cos. from $180.00 to $195.00 and gave the company a “buy” rating in a report on Thursday, June 30th. Robert W. Baird lifted their price target on shares of The Cooper Cos. from $185.00 to $196.00 and gave the company an “outperform” rating in a report on Thursday, August 18th. Stephens reiterated a “hold” rating on shares of The Cooper Cos. in a report on Saturday, June 4th. Finally, JPMorgan Chase & Co. initiated coverage on shares of The Cooper Cos. in a report on Wednesday, July 13th. They issued a “buy” rating on the stock. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The Cooper Cos. currently has a consensus rating of “Buy” and a consensus target price of $177.70.

The stock has a 50-day moving average of $184.60 and a 200-day moving average of $167.89. The company has a market capitalization of $9.07 billion, a PE ratio of 36.46 and a beta of 0.20.

The Cooper Cos. (NYSE:COO) last released its quarterly earnings results on Thursday, September 1st. The medical device company reported $2.30 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.29 by $0.01. The Cooper Cos. had a return on equity of 14.89% and a net margin of 13.14%. The company had revenue of $514.70 million for the quarter. During the same quarter in the previous year, the company posted $1.97 EPS. The business’s quarterly revenue was up 11.5% on a year-over-year basis. On average, equities research analysts expect that The Cooper Cos. will post $8.43 earnings per share for the current year.

In other The Cooper Cos. news, Director William A. Kozy acquired 270 shares of the business’s stock in a transaction on Tuesday, September 6th. The shares were bought at an average price of $186.69 per share, with a total value of $50,406.30. Following the transaction, the director now directly owns 770 shares of the company’s stock, valued at approximately $143,751.30. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Robert S. Weiss sold 151,839 shares of the company’s stock in a transaction on Monday, June 27th. The shares were sold at an average price of $163.02, for a total value of $24,752,793.78. Following the completion of the transaction, the chief executive officer now directly owns 200,617 shares in the company, valued at approximately $32,704,583.34. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.

A number of institutional investors have recently made changes to their positions in COO. Vanguard Group Inc. increased its position in shares of The Cooper Cos. by 2.8% in the second quarter. Vanguard Group Inc. now owns 3,644,352 shares of the medical device company’s stock valued at $625,262,000 after buying an additional 100,238 shares during the period. BlackRock Fund Advisors increased its position in shares of The Cooper Cos. by 4.7% in the second quarter. BlackRock Fund Advisors now owns 1,709,402 shares of the medical device company’s stock valued at $293,282,000 after buying an additional 75,993 shares during the period. State Street Corp increased its position in shares of The Cooper Cos. by 0.5% in the second quarter. State Street Corp now owns 1,557,106 shares of the medical device company’s stock valued at $267,142,000 after buying an additional 8,276 shares during the period. BlackRock Institutional Trust Company N.A. increased its position in shares of The Cooper Cos. by 3.1% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 1,472,668 shares of the medical device company’s stock valued at $252,666,000 after buying an additional 44,626 shares during the period. Finally, Westfield Capital Management Co. LP increased its position in shares of The Cooper Cos. by 6.6% in the second quarter. Westfield Capital Management Co. LP now owns 785,363 shares of the medical device company’s stock valued at $134,745,000 after buying an additional 48,718 shares during the period. 98.67% of the stock is currently owned by institutional investors.

About The Cooper Cos.

The Cooper Companies, Inc (Cooper) is a medical device company. The Company operates through two business units: CooperVision, Inc (CooperVision) and CooperSurgical, Inc (CooperSurgical). CooperVision develops, manufactures and markets a range of soft contact lenses for the vision correction market. CooperVision offers Biofinity monthly spherical, toric and multifocal lenses under the Avaira brand.

5 Day Chart for NYSE:COO

Receive News & Ratings for The Cooper Cos. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for The Cooper Cos. and related companies with Analyst Ratings Network's FREE daily email newsletter.